Tadalafil for Pulmonary Arterial Hypertension in Females
Tadalafil can be prescribed to female patients for the treatment of pulmonary arterial hypertension (PAH), specifically WHO functional class II and III disease, where it improves exercise capacity, functional class, hemodynamics, and delays time to clinical worsening.
Primary Indication: Pulmonary Arterial Hypertension
The most recent and highest-quality guidelines establish tadalafil as an approved therapy for PAH in both male and female patients. The 2015 ESC/ERS guidelines 1 and 2014 CHEST guidelines 2 provide Grade 1C to 2B recommendations for tadalafil in PAH treatment, with evidence showing:
- Improved 6-minute walk distance (6MWD) - the primary functional outcome measure
- Enhanced WHO functional class
- Delayed time to clinical worsening
- Improved cardiopulmonary hemodynamics (reduced pulmonary artery pressure and pulmonary vascular resistance)
Dosing and Administration
The approved dose is 40 mg once daily 1. Treatment with more than 40 mg daily has not been studied and is not recommended 2. The once-daily dosing offers advantages over sildenafil's three-times-daily regimen, with a longer half-life and favorable tolerability profile 3.
Treatment Algorithm for PAH
For treatment-naive patients with WHO FC II-III:
- Tadalafil can be initiated as monotherapy 2
- Initial combination therapy with ambrisentan plus tadalafil is superior to monotherapy for improving exercise capacity, supported by randomized controlled trial evidence 4, 5
For patients on background therapy:
- Adding tadalafil to existing ambrisentan improves 6MWD (mean improvement 54.4 m vs 18.3 m with placebo) 4
- Combination with endothelin receptor antagonists is well-established 6
Important Caveats
Contraindications and warnings:
- Do not combine with riociguat (soluble guanylate cyclase stimulator) - this combination is contraindicated due to risk of severe systemic hypotension 1, 5
- Monitor for side effects: headache, flushing, dyspepsia, epistaxis 1
- Regular comprehensive reassessment every 3-4 months after initiation or therapy changes 5
FDA Labeling Context
The FDA label explicitly states "Tadalafil is not indicated for use in females" 7. However, this refers specifically to the erectile dysfunction and benign prostatic hyperplasia indications. The PAH indication applies to both sexes, as demonstrated by clinical trials that included female patients (the pivotal trial included 406 PAH patients, with 53% on background bosentan therapy) 1.
Off-Label Research in Other Female Conditions
While not FDA-approved for these indications, emerging research suggests potential benefit in:
- Interstitial cystitis/bladder pain syndrome - improved symptoms and quality of life 8, 9
- Overactive bladder - reduced urgency and frequency 10
- Sexual dysfunction in diabetic women - improved genital arousal 11
These remain investigational and should not be considered standard indications.
Clinical Bottom Line
Prescribe tadalafil 40 mg once daily for female patients with WHO Group 1 PAH (functional class II-III) to improve exercise capacity and delay disease progression 2, 1. Consider upfront combination with ambrisentan for enhanced efficacy 4. Avoid combination with riociguat. The drug is well-tolerated with primarily vasodilatory side effects, and provides sustained benefit with long-term use 1, 3.